Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 228 in advanced solid tumors
NCT02437916Phase 1Terminated
- Sponsor
- Amgen
- Start
- Apr 2015
- Primary completion
- Dec 2016
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of AMG 228 in solid tumor (advanced stage), sponsored by Amgen. Primary endpoints: Subject incidence of dose limiting toxicities at 9 months, Subject incidence of treatment-emergent adverse events at 9 months and 8 more. Started Apr 2015; status: terminated.
02
Drugs
AMG 228
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02437916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02437916.